News stories about Caladrius Biosciences (NASDAQ:CLBS) have trended somewhat negative on Thursday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Caladrius Biosciences earned a news sentiment score of -0.02 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 49.8423935205478 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
A number of equities research analysts have commented on CLBS shares. Zacks Investment Research cut shares of Caladrius Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. HC Wainwright set a $7.00 target price on shares of Caladrius Biosciences and gave the stock a “buy” rating in a research note on Friday, January 19th.
Shares of Caladrius Biosciences stock traded up $0.10 on Thursday, reaching $5.99. 23,290 shares of the company’s stock were exchanged, compared to its average volume of 88,549. Caladrius Biosciences has a twelve month low of $2.63 and a twelve month high of $6.35. The stock has a market cap of $56.35, a price-to-earnings ratio of 2.81 and a beta of 1.46.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.